Abbott

The tender offer, which is being extended to allow additional time for the consummation of Abbott's acquisition of Alere, could expire at the end of August.

The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.

Abbott CEO Miles White said that he is confident that Abbott's acquisition of Alere will close as expected before the end of Q3.

About 63 million votes were in favor of the deal, representing more than 72.5 percent of all outstanding Alere shares as of the May 31 record date.

The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.

Abbott CEO Miles White said that while Alere is a bit of a fixer upper, he is pleased to have a resolution to issues surrounding the proposed acquisition. 

The firms also dropped their lawsuits against each other, and said they expect to complete the merger by the end of the third quarter.

The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.  

The FDA granted Abbott Emergency Use Authorization for the assay in serum, plasma, and urine in November.